Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)

NCT00912093 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00912093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00912093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
July 16, 2009
Completion date
October 1, 2010
Enrollment
98 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema